Drug Profile
MTL 005
Alternative Names: MTL-005Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Morvus Technology
- Developer MorEx Development Partners
- Class Metalloporphyrins; Radiation-sensitising agents; Radiosensitisers
- Mechanism of Action Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Head and neck cancer
Most Recent Events
- 22 Aug 2023 Discontinued - Phase-I for Head and neck cancer in United Kingdom (Parenteral)
- 22 Aug 2023 Discontinued - Preclinical for Breast cancer in United Kingdom (Parenteral)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Breast-cancer in United Kingdom (Parenteral, Injection)